IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer

Al-Batran, 2019, Lancet, 393, 1948, 10.1016/S0140-6736(18)32557-1 Bang, 2012, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomized controlled trial, Lancet, 379, 315, 10.1016/S0140-6736(11)61873-4 Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, New Engl J Med, 357, 1810, 10.1056/NEJMoa072252 Smalley, 2012, Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection, J Clin Oncol, 30, 2327, 10.1200/JCO.2011.36.7136 Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, New Engl J Med, 345, 725, 10.1056/NEJMoa010187 Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, New Engl J Med, 355, 11, 10.1056/NEJMoa055531 Ajani, 2006, Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response, J Clin Oncol, 24, 3953, 10.1200/JCO.2006.06.4840 Chakravarty, 2012, Intensity modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma, Int J Radiat Oncol Biol Phys, 83, 581, 10.1016/j.ijrobp.2011.07.035 Leong, 2017, TOPGEAR: A randomized, phase III Trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG, Ann Surg Oncol, 24, 2252, 10.1245/s10434-017-5830-6 Leong, 2015, TOPGEAR: Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer, BMC Cancer, 15, 532, 10.1186/s12885-015-1529-x Cats, 2018, Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial, Lancet Oncol, 19, 616, 10.1016/S1470-2045(18)30132-3 Slagter, 2018, BMC Cancer, 18, 877, 10.1186/s12885-018-4770-2 Serarslan, 2017, Dosimetric comparison of three different radiotherapy techniques in antrum-located stomach cancer, Asian Pac J Cancer Prev, 18, 741 Dahele, 2010, Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans, Med Dosim, 35, 115, 10.1016/j.meddos.2009.03.003 Alani, 2009, Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer, Int J Radiat Oncol Biol Phys, 74, 562, 10.1016/j.ijrobp.2008.09.061 Ringash, 2005, IMRT for adjuvant radiation in gastric cancer: A preferred plan?, Int J Radiat Oncol Biol Phys, 63, 732, 10.1016/j.ijrobp.2005.03.013 Trip, 2014, IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer, Radiother Oncol, 112, 289, 10.1016/j.radonc.2014.08.039 Minn, 2010, Comparison of intensity modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer, Cancer, 116, 3943, 10.1002/cncr.25246 Chopra, 2015, Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: A matched pair analysis, J Cancer Res Ther, 11, 623, 10.4103/0973-1482.150438 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480 Bang, 2019, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: Results from the phase II nonrandomized KEYNOTE-059 study, Gastric Cancer, 22, 828, 10.1007/s10120-018-00909-5 Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial, Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3